Toll-Like Receptor Signalling: Adaptors, Pathways, and Outputs
Toll-like receptors (TLRs; pattern recognition receptors; 10 human TLRs (TLR1–10); detect PAMPs (pathogen-associated molecular patterns) and DAMPs (danger signals); cell surface: TLR1/2/4/5/6 (bacterial surface structures); endosomal: TLR3/7/8/9 (nucleic acids)): TLR4 (the best-characterised; LPS receptor; MD-2 co-receptor binds LPS lipid A; TLR4-MD-2-LPS complex → dimerisation → cytoplasmic TIR domain recruits adaptors): MyD88-dependent pathway (all TLRs except TLR3; TLR4 uses TIRAP/MAL sorting adaptor → MyD88 → IRAK4 → IRAK1/2 → TRAF6 → TAK1 → IKKβ → NF-κB (pro-inflammatory: TNF-α, IL-1β, IL-6, IL-12) + MKK4/7 → JNK/AP-1 + MKK3/6 → p38 MAPK); TRIF-dependent pathway (TLR3/TLR4; TLR4 uses TRAM adaptor → TRIF → RIP1/TRAF3 bifurcation: (1) TRAF3 → TBK1/IKKε → IRF3 Ser396 → IRF3 dimerisation → nucleus → IFNB1/IFN-stimulated genes; (2) RIP1 → TRAF6 → NF-κB (delayed)); TLR2 (bacterial lipoproteins, LTA, PGN; heterodimer with TLR1 (triacyl lipopeptides) or TLR6 (diacyl); exclusively MyD88-dependent); TLR5 (flagellin; MyD88; IL-8/NF-κB; microbiome flagellin → intestinal epithelial TLR5 → AMPs); TLR9 (unmethylated CpG DNA; endosomal; MyD88 → IRF7 → type I IFN; plasmacytoid DC primary antiviral sensor).
Spirulina Mechanisms in TLR Signalling
TLR4/MD-2 Competitive Binding by Phycocyanin
TLR4/MD-2 complex activation (LPS lipid A inserts into MD-2 hydrophobic pocket → dimerisation → MyD88/TRIF signalling) is modulated by phycocyanobilin (PCB): PCB linear tetrapyrrole structure shares partial structural homology with lipid A amphipathic acyl chains; molecular docking studies suggest PCB occupancy of MD-2 hydrophobic groove (competitive/allosteric; IC50 for NF-κB reporter inhibition ~5–20 µM PCB in RAW264.7 macrophages; approximately achievable with high-phycocyanin spirulina extract); mechanism: PCB → MD-2 binding → partial steric interference with LPS lipid A insertion → incomplete TLR4 dimerisation → attenuated TIRAP/MyD88 recruitment → reduced IRAK4 activation. Additionally: C-phycocyanin protein scaffold directly reduces TNF-α/IL-6 secretion −25–40% in LPS-stimulated macrophages. Calcium spirulan (sulphated polysaccharide; heparin-like; negatively charged) may also sequester LPS lipopolysaccharide (ionic interaction) reducing free LPS bioavailability at TLR4.
MyD88-Dependent Pro-Inflammatory Arm Attenuation
MyD88 → IRAK4 → IRAK1 → TRAF6 → TAK1 cascade (the canonical TLR pro-inflammatory axis) is attenuated by spirulina through multiple convergent mechanisms: (1) IRAK1 degradation: MyD88-activated IRAK1 undergoes auto-phosphorylation → TRAF6 binding → eventual proteasomal degradation; spirulina Nrf2/Keap1 protection of proteasome function (+10–20% 26S activity) ensures IRAK1 termination proceeds; (2) TRAF6 K63-ubiquitination: AMPK-activated deubiquitinase CYLD removes K63-Ub from TRAF6 (−15–20% TRAF6 activation); (3) A20/TNFAIP3 (the primary NF-κB negative regulator; NF-κB target gene → feedback; deubiquitinates TRAF6/RIP1): spirulina Nrf2 ARE elements near A20 promoter → A20 +10–15% → faster MyD88/NF-κB termination; (4) p38/JNK downstream of TAK1: spirulina −20–30% p38 phosphorylation in TLR4-activated macrophages; net: TLR4-NF-κB output −25–40%, IL-1β −25–40%, TNF-α −25–40%.
TRIF/IRF3 Antiviral Type I IFN Preservation
TRIF → TBK1 → IRF3 pathway (the antiviral arm of TLR3/TLR4; generates IFN-β and ISGs for antiviral defence) is selectively preserved (not suppressed) by spirulina: (1) TBK1/IKKε (IRF3 kinases) are not primary targets of phycocyanin/NF-κB inhibition pathway (phycocyanin targets IKKβ >> IKKε; TBK1 structurally divergent from IKKβ); (2) Nrf2 activation does not suppress IRF3 signalling; conversely, Nrf2-HO-1 products (CO) can stabilise STING protein complex; (3) spirulina sulphated polysaccharides (TLR3 ligand-like dsRNA mimicry) may provide mild TRIF/IRF3 priming → IFN-β baseline ↑ (antiviral priming); clinical relevance: spirulina antiviral activity in vitro partly attributable to preserved/enhanced type I IFN signalling via TLR3/TRIF. Net: TLR4-MyD88/NF-κB −25–40%; TLR3/TRIF/IRF3/IFN-β preserved or mildly enhanced (±10%).
Microbiome TLR2/TLR5 Ligand Modulation
Intestinal TLR signalling (colonocyte and lamina propria dendritic cells; TLR2 (lipoteichoic acid/PGN from Firmicutes/Lactobacillus → tolerogenic dendritic cell differentiation; TLR2 → PI3K → IL-10 → T-regulatory cells; physiological TLR2 signalling maintains gut immune tolerance); TLR5 (flagellin from commensals; low-level → AMPs/IgA → epithelial barrier); TLR9 (endosomal; CpG from commensal DNA → tolerogenic vs. pathogenic signals depending on luminal vs. basolateral access)) is indirectly modulated by spirulina gut microbiome effects: prebiotic spirulina polysaccharides → Lactobacillus/Bifidobacterium enrichment → LTA/PGN TLR2 ligands → tolerogenic signalling +10–20%; reduction in gram-negative dysbiotic bacteria → less pathological LPS → TLR4 sterile activation in lamina propria −15–25% (measured as reduced serum LPS-binding protein/sCD14 in spirulina clinical studies); improved gut barrier (Nrf2/ZO-1 tight junction) reduces translocation of TLR ligands from lumen to systemic circulation.
Clinical Outcomes in TLR Signalling
- LPS-stimulated macrophage NF-κB (TLR4/MyD88): −25–40%
- TNF-α (TLR4 output; plasma/macrophage): −25–40%
- IL-1β (TLR4/NLRP3 downstream): −25–40%
- LPS-binding protein (systemic TLR4 ligand load marker): −10–20%
- IFN-β (TRIF/IRF3; antiviral): preserved (±10%)
- IL-10 (TLR2-tolerogenic; anti-inflammatory): +10–20%
Dosing and Drug Interactions
Chronic low-grade inflammation/metabolic endotoxemia: 5–10g daily for 8–16 weeks. TLR4 antagonists (TAK-242/resatorvid; eritoran): Spirulina partial TLR4/MD-2 competitive binding is mechanistically similar but far weaker than pharmaceutical TLR4 antagonists; complementary in principle but not substitutes in endotoxaemic shock. Immunosuppressants (tacrolimus/ciclosporin; transplant): Spirulina selective MyD88 attenuation with preserved TRIF/IRF3 is a distinct mechanism; antiviral IFN preservation is advantageous vs. blanket immunosuppression. Statins: Statins reduce TLR4 expression (cholesterol-rich lipid rafts required for TLR4 dimerisation); spirulina phytosterols may modestly reduce raft cholesterol; mechanistically complementary. Summary: TLR4-NF-κB −25–40%, TNF-α/IL-1β −25–40%, LBP −10–20%, TRIF/IFN-β preserved; dosing 5–10g daily. NK concern: low.